Novartis CEO Reveals Strategic Pipeline Reduction by 40% Based on Data-Driven Insights

Strategic Reduction:
Novartis has reduced its clinical-stage programs by nearly 40% in recent years, driven by data showing that the company was not getting good value from these programs[3][4].

Data-Driven Decision:
The decision to slim down the pipeline was based on a thorough analysis of data, indicating a commitment to making data-driven decisions[3][4].

CEO's Perspective:
CEO Vas Narasimhan emphasized the importance of using data to guide strategic decisions, reflecting a focus on efficiency and effectiveness in the company's research and development efforts[2].

Future Plans:
Despite the reduction, Novartis is looking to engage in more deals, potentially up to $5 billion, with a focus on early science, suggesting a strategic shift towards more promising and innovative projects[2].